<description>&lt;p class="MsoNormal"&gt;In this episode, I chat with &lt;strong&gt;Nancy Lurker,&lt;/strong&gt; CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;em&gt;Brought to you by Alcon&lt;/em&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpFirst" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Welcome to another exciting episode of Eye Care insider &lt;strong&gt;&lt;em&gt;:13&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Intro Nancy Lurker &lt;strong&gt;&lt;em&gt;:22&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Lurker's background &lt;strong&gt;&lt;em&gt;:58&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;EyePoint Pharmaceuticals: the origin and transition &lt;strong&gt;&lt;em&gt;2:29&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Yutiq and long-acting drug delivery systems &lt;strong&gt;&lt;em&gt;6:07&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Additional indications for Yutiq &lt;strong&gt;&lt;em&gt;8:30&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What is the key factor in delivering this longer durability? &lt;strong&gt;&lt;em&gt;16:13&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Any consideration of looking at superiority of visual acuity and anatomical OCT gains? &lt;strong&gt;&lt;em&gt;21:47&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? &lt;strong&gt;&lt;em&gt;24:19&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Investor information and neural protection data &lt;strong&gt;&lt;em&gt;29:01&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;What is the most important issue that the field of ophthalmology is currently facing? &lt;strong&gt;&lt;em&gt;30:38&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpLast" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;Thanks for listening &lt;strong&gt;&lt;em&gt;32:37&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt;We'd love to hear from you! Send your comments/questions to Dr. Mali at &lt;a href= "mailto:eyecareinsider@healio.com"&gt;eyecareinsider@healio.com&lt;/a&gt;. Follow us on Twitter &lt;a href= "https://twitter.com/HRheuminations"&gt;@Healio_OSN&lt;/a&gt;. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;Nancy Lurker&lt;/strong&gt; is the board director and CEO of EyePoint Pharmaceuticals.&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;Disclosures:&lt;/strong&gt; Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.&lt;/p&gt;</description>

Eye Care Insider

Joshua Mali, MD

EyePoint Pharmaceuticals' EYP-1901: Promising Novel Drug Delivery System

APR 7, 202332 MIN
Eye Care Insider

EyePoint Pharmaceuticals' EYP-1901: Promising Novel Drug Delivery System

APR 7, 202332 MIN

Description

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials. Brought to you by Alcon · Welcome to another exciting episode of Eye Care insider :13 · Intro Nancy Lurker :22 · Lurker's background :58 · EyePoint Pharmaceuticals: the origin and transition 2:29 · Yutiq and long-acting drug delivery systems 6:07 · Additional indications for Yutiq 8:30 · What is the key factor in delivering this longer durability? 16:13 · Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47 · Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19 · Investor information and neural protection data 29:01 · What is the most important issue that the field of ophthalmology is currently facing? 30:38 · Thanks for listening 32:37 We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma. Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals. Disclosures: Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.